---
title: Serum Collection Study for Assay Development
nct_id: NCT07205289
overall_status: RECRUITING
phase: PHASE1
sponsor: GPN Vaccines
study_type: INTERVENTIONAL
primary_condition: Pneumococcal Disease, Invasive
countries: Australia
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07205289.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07205289"
ct_last_update_post_date: 2025-10-03
last_seen_at: "2026-05-12T06:02:56.284Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Serum Collection Study for Assay Development

**Official Title:** A Phase 1B Open-label Study to Collect Serum Following Vaccination With Killed Whole-cell Pneumococcal Vaccine (Gamma-PN) in Adults for Use in Assay Validation

**NCT ID:** [NCT07205289](https://clinicaltrials.gov/study/NCT07205289)

## Key Facts

- **Status:** RECRUITING
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 12
- **Lead Sponsor:** GPN Vaccines
- **Conditions:** Pneumococcal Disease, Invasive, Pneumococcal Disease
- **Start Date:** 2025-10
- **Completion Date:** 2026-06
- **CT.gov Last Update:** 2025-10-03

## Brief Summary

The study will collect serum from 12 participants vaccinated with Gamma-PN to assist with assay development and validation

## Detailed Description

The study will collect serum from 12 participants vaccinated with Gamma-PN to assist with assay development and validation

Participants will receive a dose of Gamma-PN and serum will be collected pre dose and Day 28

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 69 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* good general health

Exclusion Criteria:

* no previous pneumococcal vaccine
```

## Arms

- **Gamma -PN** (EXPERIMENTAL) — Intramuscular administration 500 mcg

## Interventions

- **Gamma-PN** (BIOLOGICAL) — Killed whole-cell pneumococcal vaccine

## Primary Outcomes

- **OPA** _(time frame: 6 months)_ — Opsonophagocytic assay

## Locations (1)

- University of Adelaide Clinical Research Facility, Adelaide, South Australia, Australia — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university of adelaide clinical research facility|adelaide|south australia|australia` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07205289.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07205289*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*